Functional studies have elucidated the role of the mammalian target of rapamycin (mTOR) pathway in breast carcinogenesis, but to date, there is a paucity of data on its contribution to breast cancer risk in women of African ancestry. We examined 47 628 SNPs in 61 mTOR pathway genes in the genome wide association study of breast cancer in the African Diaspora study (The Root consortium), which included 3686 participants (1657 cases). Pathway-and gene-level analyses were conducted using the adaptive rank truncated product (ARTP) test for 10 994 SNPs that were not highly correlated (r 2 < 0.8). Odds ratio (OR) and 95% confidence interval (CI) were estimated with logistic regression for each single-nucleotide polymorphism. The mTOR pathway was significantly associated with overall and estrogen receptor-negative (ER−) breast cancer risk (P = 0.003 and 0.03, respectively). PRKAG3 (P adj = 0.0018) and RPS6KA3 (P adj = 0.061) were the leading genes for the associations with overall breast cancer risk and ER− breast cancer risk, respectively. rs190843378 in PRKAG3 was statistically significant after gene-level adjustment for multiple comparisons (OR = 0.50 for each T allele, 95% CI = 0.38-0.66, P adj = 3.6E−05), with a statistical power of 0.914. These results provide new insights on the biological relevance of the mTOR pathway in breast cancer progression and underscore the need for more genetic epidemiology studies of breast cancer in the African Diaspora.
Introduction
The mammalian target of rapamycin (mTOR) pathway is wellknown for its association with breast cancer recurrence and survival, and has been a focus for the treatment of metastatic breast cancer (1) . Its potential functions include response to cellular growth conditions and energy signalling, especially regulating tumor cell growth and proliferation (2) . In the context of cancer prevention (3), a few studies have examined the relationship between genetic variants in this pathway and the occurrence of several types of cancers, including breast cancer (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . However, the results remain inconclusive. Taking one of the most highly researched genes in the pathway, hypoxiainducible factor-1α (HIF-1α) as an example, this is a subunit of the key transcription factor (HIF-1) that regulates cellular adaptation to hypoxia (14) , the results have been inconsistent across different data sets. In a meta-analysis, one important singlenucleotide polymorphism (SNP) rs11549465 of HIF-1α was associated with significantly increased breast cancer risk in Asians (11, 12) , while another SNP, rs11549467 within the same gene was more likely to contribute to increased breast cancer susceptibility in Caucasians (10, 13) . No significant signals were identified in women of African ancestry in the African American Breast Cancer Epidemiology and Risk (AMBER) consortium (4) .
Other than exploring the genetic variant at SNP level, it is now widely accepted to explore the association between breast cancer risk and the entire mTOR pathway, considering that the effects of each gene may be small and dependent on each other because of gene-gene interactions (15, 16) . Most of the previous studies have focused on SNPs in limited number of genes in the mTOR pathway (e.g. HIF-1α, TSC2, mTOR), while some genes, such as EIF4E, a key element of this pathway, have not been studied extensively (14) . To date, only AMBER consortium has examined association between the entire mTOR pathway and breast cancer, using the approach of integrating genes within this pathway (4). They did not report significant result for pathway-level or gene-level associations after Bonferroni corrections for multiple tests.
Obesity is a confounding risk factor in African American women (prevalence: about 50%) (17) and several studies have proposed that mTOR pathway dysregulation could be a potential mechanism linking obesity to breast cancer, especially to the association with triple negative breast cancer (18) . Given the higher prevalence of triple negative breast cancer in indigenous women of African ancestry with less confounding risk of obesity (prevalence less than 20%) (19) , the current study aimed to evaluate gene variants in the mTOR pathway genes as risk factors for breast cancer in The Root Consortium, a cohort enriched for indigenous African women from Nigeria.
Method

Study participants
The study populations of The Root Consortium have been described previously (20, 21) . Briefly, this study included 3686 participants of African ancestry. Nearly half of the cases and controls were ascertained outside the United States in Nigeria (711 cases and 624 controls), Barbados (92 cases and 229 controls) and four sites in Chicago, Philadelphia, Maryland and Nashville in the USA (854 cases and 1176 controls). Patients were histologically and/or clinically diagnosed as having invasive breast cancer by the clinicians at each study site (20, 21) . Each participant provided informed consent for genomic analysis of breast cancer at each site.
SNP genotyping and imputation
Information about the genome-wide association study (GWAS) genotyping, quality control, imputation and principal component analysis (PCA) has been previously reported (20) . Briefly, genotyping was conducted using the Illumina HumanOmni2.5-8v1 array, including approximately 2.4 million genetic variants. Genotype imputation was conducted with the IMPUTE2 software (22) . With the 1000 Genomes Project Phase 1 (1092 individuals from 14 diverse populations) integrated variant set as the reference panel, 23 098 723 SNPs were imputed and included in the GWAS analyses. To account for population structure, the first 10 principal components were computed with the smartpca program in the EIGENSOFT package (23) .
Selection of candidate genes and SNPs in the mTOR pathway
A list of mTOR pathway genes was manually curated in two ways: (a) querying the Molecular Signature Database (MSigDB) (24) and (b) literature review. For each candidate gene, its start and end chromosomal positions plus 10 kb upstream and 10 kb downstream were determined using the UCSC Genome Browser (https://genome.ucsc.edu). SNPs within each gene region were extracted from The Root Consortium GWAS data and defined as 'total SNPs'. A total of 61 genes with 47 628 variants were extracted (Table 1) .
Statistical analysis
We compared all cases with controls using three approaches to examine the associations between SNPs and breast cancer risk: pathway-, geneand SNP-based analyses. As an exploratory analysis, we also examined whether SNPs are associated with ER-negative breast cancer or ER-positive breast cancer.
The pathway-and gene-based analyses were performed using the adaptive rank truncated product (ARTP) test with the R package ARTP2. The ARTP method, as one of the most popular self-contained methods, shows power advantage over other similar methods, such as aSPUpath (25, 26) . The underlying rationale is that it optimizes the selection of truncation points and correction for multiple testing by permutation analyses (15) . One SNP with a lower minor allele frequency (MAF) of every pair of SNPs with correlation r 2 ≥ 0.8 was excluded from the gene-based tests using the filter in the R package. Thus, allowing us to avoid capturing only a few association signals for some genes due to correlations between their top SNPs. Any SNPs with MAF less than 0.01were also removed from the analysis, and a set of 10 994 SNPs were selected from the 61 genes in the end. Statistical significance at the gene-based analysis was declared at the 0.00082 (=0.05/61 genes) level.
The single-SNP association tests, required as input for the ARTP analyses, were performed for SNPs in genes with a nominal P < 0.05 in the ARTP tests. We used logistic regression with case status as the outcome, and an additive model for genotype, adjusting for age (10-year groups), study site and the first four eigenvectors from principal component analysis, using SNPtest (27) . The first four eigenvectors were used to control for population stratification, as only the first four eigenvectors were associated with case status (21) . We corrected for multiple testing with a Bonferroni correction for the effective number of independent SNPs tested within a gene using Gao's SimpleM approach (28) , and called this the 'gene-wide' significance. 'Effective SNPs' (Table 1 ) means the remaining SNPs after excluding SNPs with MAF < 0.01 and SNPs with lower MAF in every pair of SNPs with correlation r 2 ≥ 0.8. The adjusted P values after Bonferroni correction were named as P adj for simplicity. We also conducted power calculations for gene-wide significant SNPs, with α as 0.05 divided by the number of effective SNPs within each gene. Furthermore, to be conservative and to better minimize any potential false positives (29), we excluded SNPs with imputation information scores <0.7.
Association signal visualization and SNP functional evaluation
Single marker associations for top genes were plotted with linkage disequilibrium (LD) data using the LocusZoom (30) Only P value for PRKAG3 remained significant after Bonferroni correction.
analysistools.nci.nih.gov/LDlink/). Information about the functionality of the gene-wide significant SNPs and their tag SNPs were explored in HaploReg v4, in which epigenomic data from the ENCODE (Encyclopedia of DNA Elements), the GTEx pilot and RegulomeDB databases were integrated (31) . Searches for eQTLs information in breast tissues were also carried out in the GTEx portal and eQTL Browser (http://eqtl.uchicago.edu/ cgi-bin/gbrowse/eqtl/).
Results
The study included 1657 breast cancer cases and 2029 controls from Barbados, Nigeria and the USA. The mean ages of cases and controls were 49.3 and 48.4 years, respectively. About 48.1% of cases with ER status were ER negative. The means of body mass index were 28.4 ± 7.0 years, 29.7 ± 7.0 years for case and control, respectively. The mTOR pathway was significantly associated with both overall and ER− breast cancer (P = 0.006 and 0.046, respectively) ( Table 1 ). The pathway level association for overall breast cancer risk was attributable to the PRKAG3 gene; after Bonferroni correction for the number of genes tested (n = 61), PRKAG3 remained significant (P adj = 0.0018). The pathway level association for ER− breast cancer risk was attributable to RPS6KA3, with its adjusted P value close to the boundary of significance (P adj = 0.061). Excluding PRKAG3 from the analysis of overall breast cancer risk, and RPS6KA3 from the analysis of ER− breast cancer risk, both pathway-level associations become non-significant (P = 0.54 and 0.85, respectively). Table 2 shows gene-wide significant variants from the SNPlevel analysis that were associated with breast cancer overall, or only with ER+ and ER− disease. The best signal locus was an upstream variant, rs190843378, in the gene PRKAG3 (Figure 1 ). The T allele of rs190843378 was significantly associated with a 50% decrease in overall breast cancer risk (odds ratio (OR) = 0.50, 95% confidence interval (CI) = 0.38-0.66, P adj = 3.6E−05), with a statistical power of 0.914 (Table 2) . In a subgroup analysis, similar odds ratios were observed for the analysis of ER+ and ER− diseases (0.56 and 0.59, respectively).
In addition, variants associated with ER+ breast cancer included rs141689493 in EIF4E (intron, OR = 2.98 for each copy of the A allele, 95% CI = 1.64-5.42, P adj = 0.03, Supplementary Figure 1A , available at Carcinogenesis Online), rs73317134 in HIF1A (intron, OR = 8.10 for each copy of the A allele, 95% CI = 2.78-23.62, P adj = 0.02, Supplementary Figure 1B , available at Carcinogenesis Online), rs75224640 in CAB39L (500b downstream variant, OR = 3.29 for each copy of the T allele, 95% CI = 2.03-5.34, P adj = 0.0005, Supplementary Figure 1C , available at Carcinogenesis Online), and rs16837635 in STRADB (intron, OR = 1.61 for each copy of the G allele, 95% CI = 1.26-2.06, P adj = 0.01, Supplementary  Figure1D , available at Carcinogenesis Online). Moreover, RPS6KA3 rs114874970 (intron, OR = 1.81 for each copy of the C allele, 95% CI = 1.39-2.36, P adj = 0.0011, Figure 2 ) was associated with an increased risk of ER− breast cancer.
The top-ranked SNPs in otherwise non-significant genes are listed in Supplementary Table 1, available at Carcinogenesis Online. Among the SNPs with MAF ≥ 0.01, rs11709841 in PIK3CB and rs116104616 in PRKAB2 were significantly associated with overall breast cancer risk after Bonferroni correction (P adj < 0.05), but only rs34717888 in AKT2 was associated with ER+ breast cancer risk. We did not find any additional eQTL information for these SNPs to further corroborate their association with gene expression and breast cancer.
Discussion
In this Root consortium study, we observed that the entire mTOR pathway was significantly associated with overall and ER− breast cancer risk (P = 0.006 and 0.046 respectively). These associations were driven primarily by two different genes (PRKAG3 and RPS6KA3) for overall and ER− breast cancer, respectively. Furthermore, a SNP within PRKAG3, rs190843378, was significantly associated with overall breast cancer risk on the gene-wide level, and the power was sufficient. To our knowledge, this is the first study to demonstrate an association of the entire mTOR pathway with breast cancer risk in women of African ancestry.
PRKAG3, as the leading gene associated with overall breast cancer risk, also named as AMPKγ3, has been considered a potential target of cancer treatment due to its function in regulating glucose/lipid metabolism and skeletal muscle glycogen content (32, 33) . However, only two studies have examined its role in the risk of breast cancer. The AMBER study did not report this association (4), while another study suggested an association between PRKAG3 and the recurrence of triple negative breast cancer in the Chinese population (5). We found a leading role for PRKAG3 in the mTOR pathway, and an independent significant SNP, rs190843378 that had a moderately protective effect for its T allele. This SNP was tagged by SNPs that overlap a transcription regulatory (enhancer) mark in breast variant human mammary epithelial cells. Considering PRKAG3's high specificity for coordinating transcription of genes critical for lipid and glucose metabolism in white glycolytic skeletal muscle (34), our findings suggest a link between obesity/metabolism or lipid/glucose metabolism and breast cancer as a new role for this gene.
RPS6KA3 (RSK2), the most significant gene associated with ER− breast cancer in our study, has also been proposed as a target of cancer therapy (35) . It is located at Xp22.2, can phosphorylate Y-box binding protein-1 (YB-1), and works as a transcription factor activated in breast cancer (36) . In contrast to results from the AMBER Consortium (4), we found that RPS6KA3 has its strongest effect of the whole pathway on ER− breast cancer through an independent significant SNP, rs114874970, with an almost double risk for its C allele. Previous gene expression studies (37) , and functional genomics evidence (Supplementary  Table 2 and Figure 2 , available at Carcinogenesis Online) support a plausible role of this gene in cancer, however, the association result in this study warrants further confirmation due to the limited power for the SNP-level result.
Other studies have shown the associations of SNPs in mTOR, HIF-1α and EIF4E with breast cancer. However, all significant SNPs in our study were novel, and there was no known information related to the reported SNP of rs181088346 in women of African ancestry (4). To date, at least four Meta analyses reported significant association between HIF-1α and breast cancer, especially in Asian women, but not in women of African ancestry (10-13). The recent AMBER study did not report an association with breast cancer risk (4). Our study did find a gene-level significant SNP of rs73317134 in HIF-1α with a more than 700% higher risk, and rs141689493 in EIF4E, with an almost 200% higher risk for their risk alleles. Both SNPs tag other SNPs that overlap a transcription regulatory (enhancer) mark in breast cells, supporting their role in promoting cellular transformation and tumorigenesis (38, 39) .
A few studies have also investigated CAB39L, STRADB and RPS6KA6 and breast cancer risk, but their potential roles in breast cancer carcinogenesis remain unclear (40) (41) (42) . In contrast to the AMBER study, as the only study involving at least one of these genes (4), we did find significant associations for these genes with the occurrence of breast cancer. In consideration of the related expression information that covers transcription regulatory (enhancer) and repressed polycomb in breast tissues, it is biologically plausible that these sequence variants affect Table 2 . Gene-wide significant tested SNPs for overall, ER+ and ER− breast cancer Gene their transcription, leading to increased breast cancer susceptibility. Further mechanistic studies are needed to confirm the involvement of these genes in breast carcinogenesis. In order to test whether the associations reported in this study can be replicated in European populations, the GAME-ON GWAS look up tool (http://gameon.dfci.harvard.edu) was searched for our top six significant SNPs in Table 2 . All of these SNPs are monomorphic in European populations. CAB39L and TRADB were reported to have different gene-level significant SNPs in Europeans. A similar result was reported by the AMBER study, which reflects the vastly different genetic backgrounds and LD patterns between women of African and European ancestries (43) . While we could not eliminate the possibility that our findings were due to chance, The Root Consortium was specifically assembled to allow us to take advantage of the short LD blocks and the relatively young age at diagnosis of breast cancer in African populations to identify risk alleles for ER− breast cancer. Nonetheless, further replication studies are needed to confirm this result.
Strengths of our study include a more comprehensive evaluation of the mTOR pathway and our inclusion of a unique population of women of African ancestry from Nigeria and Barbados than previous studies. However, several limitations should also be noted. First, despite having almost 4000 participants, the present study had limited power to detect individual SNP associations of small magnitude as well as stronger associations for rare SNPs. Nevertheless, it is one of the largest studies to date on the genetics of breast cancer in women of African ancestry. Second, although we did not have sufficient statistical power, we did an exploratory analysis by breast cancer ER subtypes. Thus, our findings require replication, as many of the gene-level associations were not significant after correction for genome-wide multiple tests. Meanwhile, the lack of functionality of the identified SNPs is a typical limitation of SNP association studies. The identified associations will certainly shed light on future experimental studies to determine their function.
In conclusion, in one of the largest breast cancer studies of women of African ancestry, we found evidence of associations between the mTOR pathway and breast cancer risk, particularly with overall and ER− breast cancer. These associations were driven primarily by two genes (PRKAG3 and RPS6KA3), which may provide new insights into the role of this pathway in breast cancer progression in women of African ancestry. 
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